SCHEMBL7081345

SCHEMBL7081345

Cc1cncn1-c1ccc([N+](=O)[O-])cc1F

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
THRB P10828 1/20 0.47
ALDH1A1 P00352 6/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.46
HIF1A Q16665 1/20 0.41
SLC6A5 Q9Y345 5/20 0.39
MEN1 O00255 2/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC6A9 P48067 4/20 0.39
S1PR4 O95977 1/20 0.38
SLC22A12 Q96S37 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480440 0.81 HTT (0.49) MAPTALDH1A1KMT2ALMNAMEN1
SCHEMBL4593671 0.80 LMNA (0.54) MAPTALDH1A1KMT2ALMNAMEN1
SCHEMBL11775775 0.76 CYP19A1 (0.43) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL1898595 0.76 KMT2A (0.54) MAPTALDH1A1KMT2AMEN1TDP1
SCHEMBL11775771 0.75 LMNA (0.58) MAPTALDH1A1KMT2ALMNAMEN1
SCHEMBL961555 0.75 ALDH1A1 (0.47) MAPTTHRBALDH1A1KMT2ALMNA
SCHEMBL3836024 0.75 ALDH1A1 (0.56) MAPTTHRBALDH1A1KMT2ALMNA
SCHEMBL7081824 0.75 ALDH1A1 (0.39) MAPTTHRBALDH1A1KMT2ALMNA
SCHEMBL14670073 0.74 ALDH1A1 (0.48) MAPTALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL9163594 0.74 FGFR1 (0.53) MAPTALDH1A1KMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6617339-B1 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens SYNGENTA LIMITED (GB) 2003-09-09 US disclosed
US-20030144263-A1 Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them SYNGENTA LIMITED (GB) 2003-07-31 US disclosed
EP-1082323-A2 OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AstraZeneca UK Limited (GB) 2001-03-14 EP disclosed
WO-1999064417-A2 OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144263-A1 Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them CYP3A5, CYP2D6, OXA1L MAPT 4796/4885THRB 1953/4885ALDH1A1 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.